

INVITATION

THURSDAY

30

SEPT

18:00 – 19:30
CET

VIRTUAL MEETING

The role of ECP in the treatment of GvHD in the new world

This information is not intended for healthcare professionals based in the US and Canada

- Moderator** **Prof Hildegard Greinix**, Medical University of Graz, Graz
- 18:00 – 18:05 **Introduction (live)**
Prof Hildegard Greinix, Graz
- 18:05 – 18:20 **Clinical experiences and potential mechanisms of ECP alone or in
combinational approaches in chronic GvHD (live)**
Prof Robert Zeiser, Medical Center University of Freiburg, Freiburg
- 18:20 – 18:35 **Clinical experiences with ECP alone or in combinational approaches – a focus
on the early treatment of acute GvHD (live)**
Prof Francis Ayuk, University Medical Center Hamburg-Eppendorf, Hamburg
- 18:35 – 18:50 **ECP as first-line strategy in the treatment of acute GvHD (live)**
Dr Florent Malard, Hôpital Saint-Antoine, Paris
- 18:50 – 19:30 **Panel Discussion (live)**
All Speakers

ECP: extracorporeal photopheresis, GvHD: graft-versus-host disease

All speakers are subject to contract.

**This is a commercial programme run by Therakos (UK) Ltd,
a Mallinckrodt Company.**

Follow the Therakos
Institute on LinkedIn



[Privacy policy](#)

For more information on THERAKOS ECP Immunomodulation™ please visit www.therakos.eu
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt
company. Other brands are trademarks of a Mallinckrodt company or their respective owners.
© 2021 Mallinckrodt. Item code: EU-2100156. Date of preparation: July 2021.

*Although we have determined that we have a legitimate interest in using your data for marketing
and sales purposes as per the terms of the current data protection legislation, you can opt-out
by replying to this mail indicating “unsubscribe” in the email body. Our Privacy Notice provides
additional information.*

INVITATION

WEDNESDAY

20

OCTOBER

18:00 – 19:30
CET

VIRTUAL MEETING

The role of ECP in the treatment of GvHD in the new world

This information is not intended for healthcare professionals based in the US and Canada

Moderator	Prof Hildegard Greinix , Medical University of Graz, Graz
18:00 – 18:05	Introduction (live) Prof Hildegard Greinix , Graz
18:05 – 18:20	Clinical experiences and potential mechanisms of ECP alone or in combinational approaches in chronic GvHD (live) Prof Robert Zeiser , Medical Center University of Freiburg, Freiburg
18:20 – 18:35	Clinical experiences with ECP alone or in combinational approaches – a focus on the early treatment of acute GvHD (live) Prof Francis Ayuk , University Medical Center Hamburg-Eppendorf, Hamburg
18:35 – 18:50	ECP as first-line strategy in the treatment of acute GvHD (live) Dr Florent Malard , Hôpital Saint-Antoine, Paris
18:50 – 19:30	Panel Discussion (live) All Speakers

ECP: extracorporeal photopheresis, GvHD: graft-versus-host disease

All speakers are subject to contract.

**This is a commercial programme run by Therakos (UK) Ltd,
a Mallinckrodt Company.**

Follow the Therakos
Institute on LinkedIn



[Privacy policy](#)

For more information on THERAKOS ECP Immunomodulation™ please visit www.therakos.eu
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.
© 2021 Mallinckrodt. Item code: EU-2100156. Date of preparation: July 2021.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our Privacy Notice provides additional information.